Señales en vivo de BDTX | Maximiza tus Ganancias con Getagraph.com

COMPRAR 136505 min ago

@ $4.67

Emitido: 14 feb 2024 @ 13:53

Retorno: 4.28%

Señal anterior: feb 13 - 15:50

Señal anterior: Vender

Retorno: 11.73 %

Live Chart Being Loaded With Signals

Commentary (17 may 2024 @ 16:00):

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors...

Stats
Volumen de hoy	1.24M
Volumen promedio	656 755
Capitalización de mercado	273.95M
EPS	$0 ( 2024-05-14 )
Próxima fecha de ganancias	( $-0.430 ) 2024-06-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.93
ATR14	$0.00800 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Campbell Shannon	Buy	61 100	Stock Option (Right to Buy)
2024-04-10	Raman Prakash	Buy	61 100	Stock Option (Right to Buy)
2024-04-10	Campbell Shannon	Buy	0
2024-04-10	Raman Prakash	Buy	0
2024-03-15	Behbahani Ali	Buy	3 166	Common Stock

INSIDER POWER
99.07
Last 97 transactions
Buy: 11 965 700 \| Sell: 275 000

Volumen Correlación

Largo: 0.14 (neutral)

Corto: 0.46 (neutral)

Signal:(40.518) Neutral

Black Diamond Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Black Diamond Correlación - Moneda/Commodity

-0.50
( neutral )

-0.64
( weak negative )

0.00
( neutral )

-0.05
( neutral )

0.62
( weak )

Black Diamond Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-437 000 (0.00 %)
EPS:	$-1.880

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-437 000 (0.00 %)
EPS:	$-1.880

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-3.24M (0.00 %)
EPS:	$-2.33

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.00347

Financial Reports:

No articles found.

Black Diamond Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Black Diamond

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.